MAP2K7 and Miyoshi myopathy: As we know, activating Ras mutations, which have a high incidence varying between 32% and 50% in MM and were featured with greater tumor burden, emphasizes the potential significance of RAS/RAF/MEK/ERK signaling as a therapeutic target (Chang-Yew Leow et al., 2013).